You are here:

everolimus (Afinitor)

Advice

following a full submission assessed under the ultra-orphan medicine process

everolimus (Afinitor®) is accepted for use within NHS Scotland.

Indication under review: for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.

Treatment with everolimus improved progression-free survival, when compared with placebo, in patients with progressive, advanced, well-differentiated, non-functioning neuroendocrine tumours of gastrointestinal or lung origin. 

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of everolimus. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.

Drug Details

Drug Name: everolimus (Afinitor)
SMC Drug ID: 1215/17
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 13 February 2017

Back